New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

CHICAGO -- Incorporating the investigational, oral selective estrogen receptor degrader (SERD) camizestrant at the first sign of emerging ESR1 mutations extended the benefit of first-line therapy ...

In terms of endoscopic improvement, the placebo group dropped 0.3 points on the UCEIS, compared with a 1.7-point drop in the 450-mg lusvertikimab group (P =0.006) and a 1.1-point drop in the 850 ...

March 20, 2025 at 12:00 AM Email Share Print Case Digest Summary ...

ZÜRICH, SWITZERLAND / ACCESSWIRE / December 3, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) (NLS), a biopharmaceutical company, is pleased to share preclinical data demonstrating ...

Departments of Medicinal Chemistry, Immunology, and Drug Metabolism, Merck Research Laboratories, Rahway, New Jersey 07065, Merck Sharp and Dohme-Neuroscience Research Center, Terlings Park, Eastwick ...

Tokyo, Japan and Cambridge, UK, 13 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes that Centessa Pharmaceuticals ...

Results from a phase 1b trial demonstrate promise for a novel treatment developed to address the needs of patients with narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Brendon Yee, PhD ...

Human epidermal growth factor receptor 2 (HER2)–targeted therapy is standard of care for HER2-positive (HER2+) breast cancer, but most patients develop progressive disease with persistent HER2 ...